Journal Mobile Options
Table of Contents
Vol. 63, No. 1, 2007
Issue release date: January 2007
Gynecol Obstet Invest 2007;63:55–60
(DOI:10.1159/000095498)

A Double-Blind Randomized Controlled Trial of Oral Misoprostol and Intramuscular Syntometrine in the Management of the Third Stage of Labor

Ng P.S. · Lai C.Y. · Sahota D.S. · Yuen P.M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The aim of this study was to compare the efficacy and safety of oral misoprostol 400 µg with intramuscular syntometrine in the management of the third stage of labor. Material and Methods: This was a double-blind randomized controlled trial conducted in a tertiary care hospital. Three hundred and fifty-five women randomized to receive either oral misoprostol 400 µg or intramuscular syntometrine in the third stage of labor were studied. The change in hemoglobin level from before to 48 h after delivery, use of additional oxytocics and treatment related side effects were the main outcome measures. Results: There were no significant differences between the two groups in terms of the change in hemoglobin level and mean blood loss. The incidence of shivering was significantly higher in the misoprostol group whilst that of vomiting was significantly higher in the syntometrine group. There were no differences in the incidence of nausea, headache, diarrhea and pyrexia between the two groups. Conclusion: Orally administeredmisoprostol at a dose of 400 µg is an acceptable alternative in preventing post-partum blood loss, as measured by the peri-partum change in hemoglobin level and was not associated with an increased incidence of side effects.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Prendiville WJ, Elbourne D, McDonald A: Active versus expectant management in the third stage of labour (Cochrane Review). Cochrane Database Syst Rev 2000;3:CD000007.
  2. Villa J, Gülmezoglu AM, Hofmeyr GJ, Forna F: Systematic review of randomized controlled trials of misoprostol to prevent postpartum hemorrhage. Am J Obstet Gynecol 2002;100:1301–1312.

    External Resources

  3. Danielsson KG, Marions L, Rodriguex A, Spur BW, Wong PY, Bygdeman M: Comparison between oral and vaginal administration of Misoprostol on uterine contractility. Obstet Gynecol 1999;93:275–280.
  4. Chua S, Arulkumaran S, Adaikan G, Ratnam SS: The effect of oxytocics stored at high temperatures on postpartum uterine activity. Br J Obstet Gynaecol 1993;100:874–875.
  5. Lumbiganon P, Hofmeyr J, Gulmerzoglu AM, Pinol A, Villar J: Misoprostol dose-related shivering and pyrexia in the third stage of labour. Br J Obstet Gynaecol 1999;106:304–308.
  6. Ng PS, Chan ASM, Sin WK, Tang LCH, Cheung KB, Yuen PM: A multicentre randomised controlled trial of oral misoprostol and i.m. syntometrine in the management of the third stage of labour. Human Reprod 2001;16:31–35.
  7. Kundodyiwa TW, Majoko F, Rusakaniko S: Misoprostol versus oxytocin in the third stage of labor. Int J Gynecol Obstet 2001;75:235–241.
  8. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD: Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann 1979;2:197–207.
  9. Nazerali H, Hogerzeil HV: The quality and stability of essential drugs in rural Zimbabwe: Controlled longitudinal study. Br Med J 1998:317:512–513.
  10. Gülmezoglu AM, Villar J, Ngoc NN, Piaggio G, Carroli G, Adetoro L, et al: The WHO multicentre double-blind randomised controlled trial to evaluate the use of misoprostol in the management of the third stage of labour. Lancet 2001;358:689–695.
  11. The American College of Obstetricians and Gynecologists: Quality Assurance in Obstetrics and Gynecology. Washington, DC, American College of Obstetricians and Gynecologists, 1989.
  12. Duthie SJ, Ven D, Yung GL, Guang DZ, Chan SY, Ma HK: Discrepancy between laboratory determination and visual estimation of blood loss during normal delivery. Eur J Obstet Gynecol Reprod Biol 1991;38:119–124.
  13. Razvi K, Chua S, Arulkumaran S, Ratnam SS: A comparison between visual estimation and laboratory determination of blood loss during the third stage of labour. Aust N Z J Obstet Gynaecol 1996;36:152–154.
  14. Oboro VO, Tabowei TO: A randomised controlled trial of misoprostol versus oxytocin in the active management of the third stage of labour. Int J Obstet Gynaecol 2003;23:13–16.
  15. Fosnochi DE, Hollifield MB, Swanson ER: Patient preference for route of pain medication delivery. J Emerg Med 2004;26:7–11.
  16. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110–115.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50